Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SUPRENZA vs COPIKTRA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Partial agonist at mu-opioid receptors; also a weak antagonist at kappa-opioid receptors. Provides analgesic effects with reduced respiratory depression compared to full agonists.
Selective phosphoinositide 3-kinase (PI3K) delta and gamma inhibitor. Blocks PI3K signaling, reducing proliferation and survival of malignant B cells and T cells, and inhibits chemotaxis and adhesion of these cells.
Management of moderate to severe chronic pain,Off-label: Treatment of opioid use disorder (as a maintenance therapy similar to buprenorphine)
Relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies,Relapsed or refractory follicular lymphoma after at least two prior systemic therapies
Adults: 200 mg orally twice daily with meals.
25 mg orally twice daily
Terminal elimination half-life is approximately 12-15 hours in patients with normal renal function, allowing for twice-daily dosing.
Terminal elimination half-life is approximately 7–10 hours in patients with relapsed or refractory CLL/SLL. Steady-state is achieved within 3–5 days of twice-daily dosing.
Primarily hepatic via CYP3A4 and CYP3A5 to norbuprenorphine (active metabolite); also undergoes glucuronidation.
Primarily metabolized by CYP3A4; also involves CYP3A5 and UDP-glucuronosyltransferases (UGTs).
Approximately 60-80% of a dose is excreted renally as unchanged drug, with 20-40% eliminated via biliary/fecal routes.
Primarily via fecal excretion (approximately 70% of total dose) as unchanged drug and metabolites, with renal excretion accounting for <15% of the dose.
Approximately 95-98% bound to plasma proteins, primarily albumin.
~84% bound to plasma proteins, primarily to albumin.
Volume of distribution is approximately 2-3 L/kg, indicating extensive tissue distribution beyond plasma volume.
Mean apparent volume of distribution (Vz/F) is approximately 100–150 L (or ~1.4–2.1 L/kg based on typical body weight), indicating extensive tissue distribution.
Oral bioavailability is approximately 70-80%.
Oral bioavailability is approximately 22% following a 25 mg capsule under fasting conditions. Absorption is increased with high-fat meals; therefore, it should be taken on an empty stomach.
e GFR <45 m L/min/1.73m²: contraindicated. e GFR ≥45: no adjustment.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended in severe renal impairment (Cr Cl <30 m L/min).
Child-Pugh Class A: no adjustment; Class B: reduce to 200 mg once daily; Class C: contraindicated.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild (Child-Pugh class A) or moderate (Child-Pugh class B), reduce dose to 25 mg once daily.
Not recommended for patients under 18 years; safety and efficacy not established.
Safety and efficacy in pediatric patients have not been established.
No specific dose adjustment; monitor renal function and use caution due to increased risk of adverse effects.
No specific dose adjustment recommended for elderly patients, but monitor for adverse effects due to potential age-related renal or hepatic impairment.
Risk of respiratory depression, especially in non-opioid-tolerant patients. Risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy. Risk of serious injury or death due to accidental exposure in children.
WARNING: FATAL AND SERIOUS TOXICITIES: Fatal and serious toxicities including infections, diarrhea or colitis, cutaneous reactions, and pneumonitis have occurred with COPIKTRA.
Respiratory depression, particularly in the first 24-72 hours of treatment; caution in patients with pulmonary disease. Risk of QT prolongation. Adrenal insufficiency. Severe hypotension. Risk of misuse, abuse, and addiction. Tolerance and physical dependence.
Fatal and serious infections,Fatal and serious diarrhea or colitis,Fatal and serious cutaneous reactions,Fatal and serious pneumonitis,Neutropenia,Hepatotoxicity,Embryo-fetal toxicity
Hypersensitivity to buprenorphine or any component of the formulation. Severe respiratory insufficiency. Acute or severe bronchial asthma. Gastrointestinal obstruction, including paralytic ileus.
Concurrent use with strong CYP3A inhibitors due to increased toxicity risk
No significant food interactions. Grapefruit juice may increase buprenorphine levels; avoid large quantities.
Avoid grapefruit and grapefruit juice; may increase dupilumab exposure. Take with or without food.
Supr ENza (testosterone) is contraindicated in pregnancy due to virilization of female fetus. First trimester: high risk of clitoromegaly, labial fusion, and urogenital sinus abnormalities. Second and third trimesters: risk of continued virilization, including phallic enlargement and ambiguous genitalia. Fetal growth restriction may occur.
COPIKTRA (duvelisib) is contraindicated in pregnancy. Based on its mechanism of action as a PI3K inhibitor and animal studies, it can cause fetal harm. In animal reproduction studies, duvelisib was embryotoxic and fetotoxic at maternal exposures below the recommended human dose. There are no adequate human data. Risks include embryo-fetal mortality, structural abnormalities, and growth impairment across all trimesters.
Testosterone is present in breast milk; M/P ratio not reported. Avoid breastfeeding due to potential for androgenization of the infant. Use only if clearly needed and no safer alternative.
No data on duvelisib presence in human milk, effects on breastfed infant, or milk production. Due to potential for serious adverse reactions (e.g., immunosuppression, neutropenia), advise women not to breastfeed during treatment and for at least 1 month after last dose. M/P ratio unknown.
Not applicable; Supr ENza is contraindicated in pregnancy. No dose adjustments are recommended as use is avoided entirely.
No pharmacokinetic studies have been conducted in pregnant women. No dosing adjustments are recommended because duvelisib is contraindicated in pregnancy. If used inadvertently, the standard dose (25 mg twice daily) should be maintained until drug discontinuation is considered.
SUPRENZA (buprenorphine/naloxone) sublingual film is used for opioid dependence. Monitor for respiratory depression especially when combined with benzodiazepines or alcohol. The naloxone component is poorly absorbed sublingually but precipitates withdrawal if injected. Administer only after clear signs of withdrawal to avoid precipitated withdrawal. Adjust dose in hepatic impairment as buprenorphine is hepatically metabolized.
Monitor for hepatotoxicity with baseline and periodic liver function tests; avoid live vaccines; consider dose reduction in patients with moderate hepatic impairment (Child-Pugh B); watch for infections due to neutropenia; contraindicated in severe hepatic impairment (Child-Pugh C).
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Place film under the tongue until fully dissolved; do not chew or swallow.,Avoid alcohol and benzodiazepines as they can cause severe respiratory depression.,Keep out of reach of children; accidental exposure can be fatal.,Do not abruptly stop; withdrawal symptoms may occur.,Store at room temperature away from moisture and heat.
Take exactly as prescribed; do not change dose without consulting your doctor.,Avoid grapefruit and grapefruit juice during treatment.,Report any signs of infection (fever, chills, cough) or jaundice (yellowing skin/eyes) immediately.,Use effective contraception during treatment and for at least 1 month after the last dose.,Do not receive live vaccines during or shortly after treatment.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SUPRENZA vs COPIKTRA, answered by our medical review team.
SUPRENZA is a Sympathomimetic Anorectic that works by Partial agonist at mu-opioid receptors; also a weak antagonist at kappa-opioid receptors. Provides analgesic effects with reduced respiratory depression compared to full agonists.. COPIKTRA is a PI3K Inhibitor Antineoplastic that works by Selective phosphoinositide 3-kinase (PI3K) delta and gamma inhibitor. Blocks PI3K signaling, reducing proliferation and survival of malignant B cells and T cells, and inhibits chemotaxis and adhesion of these cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SUPRENZA and COPIKTRA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SUPRENZA is: Adults: 200 mg orally twice daily with meals.. The standard adult dose of COPIKTRA is: 25 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SUPRENZA and COPIKTRA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SUPRENZA is classified as Category C. SuprENza (testosterone) is contraindicated in pregnancy due to virilization of female fetus. First trimester: high risk of clitoromegaly, labial fusion, and urogenital sinus abnorm. COPIKTRA is classified as Category C. COPIKTRA (duvelisib) is contraindicated in pregnancy. Based on its mechanism of action as a PI3K inhibitor and animal studies, it can cause fetal harm. In animal reproduction studi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.